Cisplatin Modified DNA Antibody (CP9/19) - BSA Free

• Reactivity: All-NA
• Applications: DB, ELISA, Flow, IHC, IP
• Clone: CP9/19
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

Cisplatin Modified DNA Antibody (CP9/19) - BSA Free Summary

• Description: Novus Biologicals Rat Cisplatin Modified DNA Antibody (CP9/19) - BSA Free (NBP2-50165) is a monoclonal antibody validated for use in IHC, ELISA, Flow and IP. Anti-Cisplatin Modified DNA Antibody: Cited in 3 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Cisplatin modified native DNA
• Specificity: CP9/19 recognises only the intra-strand cross-links formed by Cisplatin between adjacent purines.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Dot Blot 1:100 - 1:2000
  • ELISA 1:100 - 1:2000
  • Flow Cytometry 1:10-1:1000
  • Immunohistochemistry 1:10 - 1:500
  • Immunohistochemistry-Paraffin
  • Immunoprecipitation 1:10 - 1:500
• Application Notes: Positive control(s): RNA/DNA. Use in Immunohistochemistry-paraffin reported in scientific literature (PMID: 31673101).

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein G purified

Alternate Names for Cisplatin Modified DNA Antibody (CP9/19) - BSA Free

• ICR4

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Cisplatin Modified DNA Antibody (NBP2-50165)(3)

Publications using NBP2-50165

• Tesfay L, Paul BT, Hegde P et al. Complementary anti-cancer pathways triggered by inhibition of sideroflexin 4 in ovarian cancer Scientific reports 2022-11-19 [PMID: 36402786]
• Federico C, Sun J, Muz B et al. Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side-Effect Profile Int J Radiat Oncol Biol Phys 2020-11-27 [PMID: 33253820]
• Kita Y, Hamada A, Saito R et al. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies Br. J. Cancer 2019-11-01 [PMID: 31673101] (IHC-P, Human)